MIRA INFORM REPORT

Report No. :	357218
Report Date :	28.12.2015

IDENTIFICATION DETAILS

Name :	MANHATTAN PHARMA

Registered Office :	Plot # 209/3B, Sector 5, Korangi Industrial Area, Karachi

Country :	Pakistan

Date of Incorporation :	1996

Legal Form :	Partnership business

Line of Business :	Manufacture & Marketing of Veterinary Pharmaceuticals and Feed Additives.

No. of Employee :	79

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Satisfactory

Payment Behaviour :	No complaints

Litigation :	Clear

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – March 31, 2015

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Pakistan

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

PAKISTAN ECONOMIC OVERVIEW

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fourth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to diversify its exports has left the country vulnerable to shifts in world demand. Official unemployment was 6.9% in 2014, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Pakistan's human development continues to lag behind most of the region.. As a result of political and macroeconomic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 to preventa balance of payments crisis, but the IMF ended the Arrangement early because of Pakistan's failure to implement required reforms. The economy has stabilized, it continues to underperform and foreign investment has not returned to levels seen during the mid-2000s, due to investor concerns related to governance, electricity shortages, , and a slow-down in the global economy. Remittances from overseas workers, averaging more than$1 billion a month, remain a bright spot for Pakistan. After a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to a deficit where it remained through 2014, spurred by higher prices for imported oil and lower prices for exported cotton. In September 2013, after facing balance of payments concerns, Pakistan entered into a three-year, $6.7 billion IMF Extended Fund Facility. The Sharif government has since made modest progress implementing fiscal and energy reforms, and in December 2014 the IMF described Pakistan's progress as "broadly on track." Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3.5% per year from 2008 to 2014. Pakistan must address long standing issues related to government revenues and the electricity and natural gas sectors in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors.

Source : CIA

Company name

MANHATTAN PHARMA

Full Address

Registered Address

Plot # 209/3B, Sector 5, Korangi Industrial Area, Karachi, Pakistan

Tel #	92 (21) 35052673, 35052674
Fax #	92 (21) 35052696
Email	hashmi53@yahoo.com

Short Description Of Business

a.	Nature of Business	Manufacture & Marketing of Veterinary Pharmaceuticals and Feed Additives
b.	Year Established	1996
c.	National Tax #	2725562 – 0

Branches

None

Legal Status

Subject Company was established as a Partnership business in 1996

Details of Management

Names

Nationality

Address

Occupation

Designation

Mr. Aqeel Hashmi

Mr. Syed Ibnul Hassan Hashmi

Mr. Syed Muhammad Shakeel Hashmi

Pakistani

Plot # 209/3B, Sector 5, Korangi Industrial Area, Karachi

Business

CEO / Managing Partner

Partner

Associates

A. Subsidiary

None

B. Associated Companies

- Do -

Business Activities

Subject Company is engaged in manufacture & marketing of Veterinary Pharmaceuticals and Feed Additives.

It purchases raw material against D/A, D/P basis.

Its mainly import from Companies belongs to China, Korea, Austria, Germany, Holland & India

Its major customers are Private Companies, Traders, Poultry Companies etc.

Subject operates from caption leased factory premises of area measuring 4,000 Sq. Yards situated at industrial area of Karachi.

Subject employs about 79 persons in its set up.

Annual Sales Volume

Year

In Pak Rupees

2014

120,000,000/- (Estimated)

Capacity & Production

The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.

Customers

Mainly Livestock Farmers, Traders, Veterinary Government Hospitals, Poultry Feed Millers, Poultry Home Mixtures, Poultry Farmers, Private Veterinary Practitioners

Bankers

(1) Faysal Bank Limited, Pakistan.

(2) MCB Bank Limited, Pakistan.

(3) Soneri Bank Limited, Pakistan.

(4) Bank Al-Habib Limited, Pakistan.

Foreign Exchange Rates

Currency	Unit	Pakistani Rupee
US Dollar	1	Rs. 106.20
UK Pound	1	Rs. 158.20
Euro	1	Rs. 115.00

Comments

Subject Company was established in 1996 and is engaged in manufacture & marketing of Veterinary Pharmaceuticals and Feed Additives. Market reputation is good and trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.66.20
UK Pound	1	Rs.98.30
Euro	1	Rs.72.41
PKR	1	Rs.0.63

Note : Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	KAS

Report Prepared by :	ANK

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
--	NB	New Business	--

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.